Patents by Inventor Lori Kunkel

Lori Kunkel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of using bispecific CD33 and CD3 binding proteins
    Patent number: 11753469
    Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: September 12, 2023
    Assignee: Anji Bruno, LLC
    Inventors: Luke Evnin, Jeanmarie Dean Guenot, Lori Kunkel
  • DOSAGE AND ADMINISTRATION OF ANTI-ERBB3 (HER3) MONOCLONAL ANTIBODIES TO TREAT TUMORS ASSOCIATED WITH NEUREGULIN 1 (NRG1) GENE FUSIONS
    Publication number: 20220288204
    Abstract: Provided are methods for the clinical treatment of tumors associated with NRG1 gene fusions using anti-ERBB3 antibodies.
    Type: Application
    Filed: March 10, 2022
    Publication date: September 15, 2022
    Inventors: Shawn M. LELAND, Lori Kunkel, Doug Plessinger, Valerie Malyvanh Jansen
  • Methods of Using Bispecific CD33 and CD3 Binding Proteins
    Publication number: 20210032339
    Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
    Type: Application
    Filed: August 10, 2020
    Publication date: February 4, 2021
    Inventors: Luke Evnin, Jeanmarie Dean Guenot, Lori Kunkel
  • Bispecific CD33 and CD3 Binding Proteins
    Publication number: 20210024654
    Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
    Type: Application
    Filed: March 18, 2020
    Publication date: January 28, 2021
    Inventors: Kristina Ellwanger, Luke Evnin, Judith A. Fox, Ivica Fucek, Jeanmarie Guenot, Stefan Knackmuss, Lori Kunkel, Melvyn Little, Vera Molkenthin, Erich Rajkovic, Uwe Reusch, Claudia Wall, Michael Weichel, Eugene Zhukovsky
  • Methods of using bispecific CD33 and CD3 binding proteins
    Patent number: 10738118
    Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: August 11, 2020
    Assignee: Amphivena Therapeutics, Inc.
    Inventors: Luke Evnin, Jeanmarie Guenot, Lori Kunkel
  • Bispecific CD33 and CD3 binding proteins
    Patent number: 10626190
    Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: April 21, 2020
    Assignee: Amphivena Therapeutics, Inc.
    Inventors: Kristina Ellwanger, Luke Evnin, Judith A. Fox, Ivica Fucek, Jeanmarie Guenot, Stefan Knackmuss, Lori Kunkel, Melvyn Little, Vera Molkenthin, Erich Rajkovic, Uwe Reusch, Claudia Wall, Michael Weichel, Eugene Zhukovsky
  • Bispecific CD33 and CD3 Binding Proteins
    Publication number: 20180291113
    Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
    Type: Application
    Filed: October 27, 2017
    Publication date: October 11, 2018
    Inventors: Kristina ELLWANGER, Luke EVNIN, Judith A. FOX, Ivica FUCEK, Jeanmarie GUENOT, Stefan KNACKMUSS, Lori KUNKEL, Melvyn LITTLE, Vera MOLKENTHIN, Erich RAJKOVIC, Uwe REUSCH, Claudia WALL, Michael WEICHEL, Eugene ZHUKOVSKY
  • TREATMENT OF AUTOIMMUNE DISEASES
    Publication number: 20180264107
    Abstract: The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.
    Type: Application
    Filed: May 17, 2018
    Publication date: September 20, 2018
    Applicants: Genentech, Inc., Biogen Inc.
    Inventors: John G. Curd, Antonio J. Grillo-Lopez, Lori A. Kunkel
  • METHODS OF USING BISPECIFIC CD33 AND CD3 BINDING PROTEINS
    Publication number: 20180148507
    Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
    Type: Application
    Filed: May 26, 2016
    Publication date: May 31, 2018
    Inventors: Luke EVNIN, Jeanmarie GUENOT, Lori KUNKEL
  • Bispecific CD33 and CD3 binding proteins
    Patent number: 9803029
    Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: October 31, 2017
    Assignee: AMPHIVENA THERAPEUTICS, INC.
    Inventors: Kristina Ellwanger, Luke Evnin, Judith A. Fox, Ivica Fucek, Jeanmarie Guenot, Stefan Knackmuss, Lori Kunkel, Melvyn Little, Vera Molkenthin, Erich Rajkovic, Uwe Reusch, Claudia Wall, Michael Weichel, Eugene Zhukovsky
  • Optimized anti-CD30 antibodies
    Patent number: 9574006
    Abstract: An antibody that targets CD30, wherein the antibody comprises at least one modification relative to a parent antibody and the antibody binds with altered affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the anti-CD30 antibody.
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: February 21, 2017
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, John R. Desjarlais, Philip W. Hammond, David F. Carmichael, Bao-lu Chen, Seung Y. Chu, Sher Bahadur Karki, Lori Kunkel
  • Bispecific CD33 and CD3 Binding Proteins
    Publication number: 20160194409
    Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
    Type: Application
    Filed: November 10, 2015
    Publication date: July 7, 2016
    Inventors: Kristina ELLWANGER, Luke EVNIN, Judith A. FOX, Ivica FUCEK, Jeanmarie GUENOT, Stefan KNACKMUSS, Lori KUNKEL, Melvyn LITTLE, Vera MOLKENTHIN, Erich RAJKOVIC, Uwe REUSCH, Claudia WALL, Michael WEICHEL, Eugene ZHUKOVSKY
  • Bispecific CD33 and CD3 Binding Proteins
    Publication number: 20160002333
    Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
    Type: Application
    Filed: March 9, 2015
    Publication date: January 7, 2016
    Inventors: Kristina ELLWANGER, Luke EVNIN, Judith A. FOX, Ivica FUCEK, Jeanmarie GUENOT, Stefan KNACKMUSS, Lori KUNKEL, Melvyn LITTLE, Vera MOLKENTHIN, Erich RAJKOVIC, Uwe REUSCH, Claudia WALL, Michael WEICHEL, Eugene ZHUKOVSKY
  • Bispecific CD33 and CD3 binding proteins
    Patent number: 9212225
    Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: December 15, 2015
    Assignee: AMPHIVENA THERAPEUTICS, INC.
    Inventors: Kristina Ellwanger, Luke Evnin, Judith A. Fox, Ivica Fucek, Jeanmarie Guenot, Stefan Knackmuss, Lori Kunkel, Melvyn Little, Vera Molkenthin, Erich Rajkovic, Uwe Reusch, Claudia Wall, Michael Weichel, Eugene Zhukovsky
  • TREATMENT OF MULTIPLE SCLEROSIS
    Publication number: 20140134164
    Abstract: The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.
    Type: Application
    Filed: January 17, 2014
    Publication date: May 15, 2014
    Applicants: BIOGEN IDEC INC., GENENTECH, INC.
    Inventors: John G. Curd, Lori A. Kunkel, Antonio J. Grillo-Lopez
  • TREATMENT OF MULTIPLE SCLEROSIS
    Publication number: 20130273042
    Abstract: The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.
    Type: Application
    Filed: June 11, 2013
    Publication date: October 17, 2013
    Inventors: John G. Curd, Lori A. Kunkel, Antonio J. Grillo-Lopez
  • TREATMENT OF MULTIPLE SCLEROSIS
    Publication number: 20120201818
    Abstract: The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.
    Type: Application
    Filed: April 18, 2012
    Publication date: August 9, 2012
    Inventors: John G. Curd, Lori A. Kunkel, Antonio J. Grillo-Lopez
  • Optimized Anti-CD30 Antibodies
    Publication number: 20120014943
    Abstract: An antibody that targets CD30, wherein the antibody comprises at least one modification relative to a parent antibody and the antibody binds with altered affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the anti-CD30 antibody.
    Type: Application
    Filed: June 17, 2011
    Publication date: January 19, 2012
    Applicant: Xencor, Inc.
    Inventors: Gregory Alan Lazar, John R. Desjarlais, Philip W. Hammond, David F. Carmichael, Bao-Iu Chen, Seung Y. Chu, Sher Bahadur Karki, Lori Kunkel
  • Optimized anti-CD30 antibodies
    Patent number: 7973136
    Abstract: An antibody that targets CD30, wherein the antibody comprises at least one modification relative to a parent antibody and the antibody binds with altered affinity to an FcgR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the anti-CD30 antibody.
    Type: Grant
    Filed: October 6, 2006
    Date of Patent: July 5, 2011
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, John R. Desjarlais, Philip W. Hammond, David F. Carmichael, Bao-lu Chen, Seung Y. Chu, Sher Bahadur Karki, Lori Kunkel
  • Treatment of Autoimmune Diseases
    Publication number: 20110008336
    Abstract: The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.
    Type: Application
    Filed: September 20, 2010
    Publication date: January 13, 2011
    Applicant: Genentech, Inc.
    Inventors: John G. Curd, Lori A. Kunkel, Antonio J. Grillo-Lopez